Stock listing

NASDAQ:OBIO Orchestra BioMed Holdings, Inc. Stock

Home listing (NASDAQ) of Orchestra BioMed Holdings, Inc.

Follow Orchestra BioMed Holdings, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:OBIO

$6.58 USD -0.88 (-11.8%)

Close on Nov 20, 2026

Past year +48.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.47 – $7.14 USDNov 20, 2026
Volume
554,315 sharesNov 20, 2026
Market cap
$517.9M USDAt the close on Nov 20, 2026 · price × 78.70M shares outstanding
52-week range
$3.46 – $7.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.48M USDMedian day 284,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Orchestra BioMed Holdings, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:OBIO · Home$6.58 USD-0.88 (-11.8%)554,315$6.89$7.14$6.47$7.46Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.58-0.88-11.8%$6.89$7.14$6.47554,315
$7.46+0.49+7.0%$7.02$7.825$7.001,203,905
$6.97-0.15-2.1%$7.10$7.365$6.95551,845
$7.12-0.13-1.8%$7.16$7.45$7.04755,454
$7.25+1.10+17.9%$6.25$7.365$6.001,564,544
$6.15+0.14+2.3%$6.08$6.18$5.70631,014
$6.01+0.28+4.9%$5.75$6.34$5.73452,902
$5.73+0.03+0.5%$5.83$5.90$5.69485,538
$5.70+0.02+0.4%$5.73$5.88$5.36781,799
$5.68+0.06+1.1%$5.135$6.04$5.1351,740,882
$5.62-0.38-6.3%$6.00$6.00$5.60253,745
$6.00+0.44+7.9%$5.815$6.161$5.78335,412
$5.56-0.13-2.3%$5.70$5.98$5.52273,209
$5.69-0.22-3.7%$5.92$6.02$5.66317,495
$5.91-0.18-3.0%$6.07$6.075$5.845231,581
$6.09+0.10+1.7%$6.05$6.16$6.00274,563
$5.99+0.21+3.6%$5.76$6.03$5.685427,145
$5.78+0.23+4.1%$5.842$5.842$5.52376,769
$5.55-0.04-0.7%$5.58$5.655$5.52242,656
$5.59+0.12+2.2%$5.46$5.66$5.39262,000
$5.47-0.335-5.8%$5.72$5.789$5.43390,900
$5.805-0.015-0.3%$5.83$5.865$5.57486,000
$5.82+0.17+3.0%$5.65$6.17$5.53992,100
$5.65+0.20+3.7%$5.49$5.73$5.415226,600
$5.45-0.29-5.1%$5.75$5.87$5.37473,700
$5.74+0.10+1.8%$5.68$5.85$5.66253,400
$5.64-0.08-1.4%$5.70$5.86$5.60222,900
$5.72-0.19-3.2%$5.87$5.87$5.71204,800
$5.91-0.04-0.7%$5.93$5.99$5.39237,900
$5.95+0.22+3.8%$5.73$5.965$5.56229,300
$5.73+0.07+1.2%$5.75$5.83$5.51241,900
$5.66-0.18-3.1%$5.79$5.859$5.64241,200
$5.84-0.19-3.2%$6.05$6.12$5.82213,100
$6.03+0.08+1.3%$5.89$6.09$5.79284,800
$5.95-0.40-6.3%$6.40$6.44$5.77421,100
$6.35+0.13+2.1%$6.27$6.50$6.23389,900
$6.22+0.14+2.3%$6.09$6.29$6.00270,700
$6.08+0.19+3.2%$5.89$6.09$5.83237,100
$5.89-0.06-1.0%$5.95$5.95$5.80177,500
$5.950.000.0%$5.99$6.17$5.86248,800
$5.95+0.02+0.3%$5.90$6.05$5.75262,900
$5.93-0.29-4.7%$6.10$6.20$5.90242,300
$6.22-0.03-0.5%$6.15$6.48$6.053342,900
$6.25+0.17+2.8%$6.04$6.29$5.85433,200
$6.08+0.30+5.2%$5.74$6.30$5.711,137,400
$5.78-0.23-3.8%$6.03$6.26$5.73411,200
$6.01-0.03-0.5%$6.05$6.28$5.93297,200
$6.04+0.14+2.4%$6.00$6.13$5.93228,400
$5.90-0.22-3.6%$6.07$6.20$5.74383,500
$6.12+0.31+5.3%$5.87$6.25$5.76464,400
$5.81+0.36+6.6%$5.845$6.08$5.68761,500
$5.45+0.02+0.4%$5.31$5.46$5.261198,600
$5.43+0.35+6.9%$5.18$5.51$4.80359,300
$5.08+0.34+7.2%$4.71$5.14$4.71478,100
$4.74-0.21-4.2%$4.97$4.97$4.71325,600
$4.95+0.05+1.0%$4.92$5.01$4.83240,400
$4.90-0.14-2.8%$5.02$5.349$4.875214,500
$5.04-0.145-2.8%$5.23$5.33$5.004276,600
$5.185+0.075+1.5%$5.23$5.23$5.06154,500
$5.11-0.15-2.9%$5.23$5.42$5.10220,500
$5.26-0.10-1.9%$5.36$5.45$5.16391,700
$5.36-0.08-1.5%$5.37$5.50$5.35169,600
$5.44+0.08+1.5%$5.35$5.48$5.21249,500
$5.36-0.07-1.3%$5.45$5.53$5.27276,700
$5.43-0.12-2.2%$5.53$5.58$5.38209,600
Ticker
NASDAQ:OBIO
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Orchestra BioMed Holdings, Inc. news

Orchestra BioMed Holdings, Inc. on 6ix

News releases
24 in the last 12 months · 82 in all · newest Nov 17, 2026 · oldest 2022
Decks
21 decks · latest October 2026

Where Orchestra BioMed Holdings, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:OBIO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:OBIOBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$417.1M USD
P/E
Loss
EV/sales
13.4×
EV/EBITDA
Negative EBITDA
Price/book
66.5×
Gross margin
99.4%
Operating margin
−195.4%
Net margin
−182.5%
Debt to equity
0.1×
Beta vs S&P 500
1.59

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
12.43 USD · Analysts' mean
EPS, year to Dec 2026
-1.52 · 6 analysts
Revenue, year to Dec 2026
451.1K · 7 analysts

Team and board

Officers

OfficerRole
David P. HochmanChairman, Chief Executive Officer
Andrew TaylorChief Financial Officer
Darren R. ShermanPresident, Chief Operations Officer, Director
Amy BermanVice President, Clinical Operations
Avi FischerSenior Vice President, Medical Affairs and Innovation
Bill LittleExecutive Vice President, Corporate Development and Strategy
Bob LaughnerSenior Vice President of Regulatory and Quality
Hans-Peter StollSenior Vice President, Medical Director
Heather BuckleyVice President, Marketing
John SieckhausVice President, Global Field Clinical Engineering
Juan LorenzoSenior Vice President of Product Development
Kunal FalduVice President, Pharmaceutical Development, Focal Therapies
Lisa DanielsVice President, Human Resources
Mark PomeranzExecutive Vice President and General Manager, Interventional Therapies
William BaumbachVice President, Scientific Affairs, Focal Therapies
Ziv BelskyVice President, Research & Development, Bioelectronic Therapies
Yuval MikaGeneral Manager and Chief Technology Officer, Bioelectronic Therapies

Board

DirectorRole
David P. HochmanChairman, Chief Executive Officer
Chris ClearyBoard Member
Darren R. ShermanPresident, Chief Operations Officer, Director
David PacittiBoard Member
Eric FainChair of the Compensation Committee
Jason AryehChair of the Nominating and Corporate Governance Committee
John MackBoard Member
Pamela ConnealyBoard Member, Audit Committee Chair

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+4.9%
Q2 2026Aug 10, 2026 · After close−1.4%
Q1 2026May 13, 2026+1.2%
Q4 2025Mar 12, 2026 · Before open−4.8%
Q3 2025Nov 10, 2025 · After close+8.5%
Q2 2025Aug 12, 2025 · Before open+7.9%
Q1 2025May 12, 2025 · After close+10.9%
Q4 2024Mar 31, 2025−26.4%
Q3 2024Nov 12, 2024 · After close+7.2%
Q2 2024Aug 12, 2024 · After close−2.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close+13.0%
Q4 2023Mar 27, 2024 · After close−0.7%
Q3 2023Nov 13, 2023 · After close+13.1%
Q2 2023Aug 10, 2023 · After close−1.6%
Q1 2023May 12, 2023 · Before open0.0%
Q4 2022Jan 25, 2023+30.5%
Q3 2022Dec 16, 2022 · After close+0.5%
Q2 2022Aug 15, 20220.0%
Q1 2022May 13, 2022+0.1%
Q4 2021Mar 31, 20220.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck30 slidesOctober 2026
Investor Presentation (September 2026)Investor deck26 slidesSep 8, 2026
Technical Presentation (2026)Technical12 slides2026
CRT 2026Conference13 slides2026
Corporate Update (November 2025)Corporate update17 slidesNov 13, 2025
Investor Presentation (October 2025)Investor deck24 slidesOct 30, 2025
Investor Presentation (March 2025)Investor deck28 slidesMar 3, 2025
THT 2025Conference13 slides2025
Investor Day (June 2024)Investor day57 slidesJun 11, 2024
Investor Day (June 2024)Investor day56 slidesJun 11, 2024
All 21 decks
DeckKindSlidesDate
Investor Presentation (March 2024)Investor deck23 slidesMar 7, 2024
Investor Presentation (November 2023)Investor deck22 slidesNov 14, 2023
Investor Presentation (October 2023)Investor deck21 slidesOct 10, 2023
Investor Presentation (September 2023)Investor deck11 slidesSeptember 2023
Investor Presentation (July 2023)Investor deck21 slidesJul 13, 2023
Investor Presentation (July 2023)Investor deck21 slidesJul 12, 2023
Investor Presentation (June 2023)Investor deck26 slidesJun 8, 2023
Investor Presentation (March 2023)Investor deck27 slidesMar 13, 2023
Health Sciences Acquisitions Corp 2 — SPAC Merger (December 2022)SPAC merger34 slidesDec 1, 2022
Health Sciences Acquisitions Corp 2 — SPAC Merger (July 2022)SPAC merger32 slidesJul 5, 2022
Technical PresentationTechnical19 slides

Open Decks

Financings

RaiseDate
Public offering of shares of common stock
Closed: US$80.5M raised · US$5 a share · Piper Sandler +3
Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG, H.C. Wainwright & Co.
Use of proceeds: Fund AVIM Therapy program and BACKBEAT Trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes
Nov 10, 2026
Public offering of shares of common stock
Announced: Piper Sandler +2
Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG
Use of proceeds: Fund AVIM Therapy program and BACKBEAT trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes
Nov 5, 2026
Strategic investment of strategic capital
Closed: US$35M raised
Buyers: Medtronic (Medtronic's total capital contribution to Orchestra BioMed is nearly $82 million, including this investment); Ligand (Ligand has now provided $40 million in total capital to the Company)
Aug 10, 2026
Strategic investment of non-voting convertible preferred stock
Announced: US$20M
Buyers: Terumo ($20 million in a new series of non-voting preferred stock)
Use of proceeds: Advance both pivotal stage programs to key clinical and regulatory milestones
Oct 28, 2025
Public offering of common stock and pre-funded warrants
Announced: about US$40M · US$2.75 a share · Piper Sandler +1
Dealers: Piper Sandler (co-lead), TD Cowen (co-lead)
Use of proceeds: Fund AVIM therapy program and BACKBEAT study, Virtue SAB program and trial, other product candidates, working capital and general corporate purposes
Aug 1, 2025
Tiered royalty on future sales of AVIM therapy and Virtue SAB
Announced: US$35M
Buyers: Ligand ($20 million at closing and an additional $15 million at the nine-month anniversary, subject to conditions)
Use of proceeds: To advance its late-stage partnered cardiology programs (AVIM therapy and Virtue SAB)
Jul 31, 2025
Private placement of common stock
Announced: US$5M
Buyers: Ligand ($5 million of common stock)
Jul 31, 2025
Private placement of common stock
Announced: US$10M
Buyers: Medtronic ($10 million of common stock)
Jul 31, 2025
Secured subordinated promissory note convertible to prepaid revenue share
Announced: US$20M
Buyers: Medtronic ($20 million secured subordinated promissory note)
Jul 31, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Health Sciences Acquisitions Corp 2, a blank check company (SPAC). Priced at US$10.00 a share on Aug 3, 2020.

Price
US$10.00 a share
Shares offered
13,913,044 ordinary shares
Offering size
US$139.1 million
Underwriters' option
Up to 2,086,956 more shares
Listing
HSAQ on the Nasdaq Capital Market
Underwriters
Chardan, Barclays · In the order on the cover
Shares delivered
On or about Aug 3, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJun 22, 2020
Filed publiclyJul 17, 2020
Amended twiceNewest Jul 28, 2020
Shares registered with an exchangeAug 3, 2020
Declared effective by the SECAug 3, 2020
Final prospectus, with the priceAug 5, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Aug 5, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue33.5M2.64M2.76M3.53M-782.0K5.70M
Cost of revenue190.0K204.0K186.0K211.0K199.0K145.0K
Gross profit33.3M2.43M2.57M3.21M-981.0K5.56M
Research and development58.2M42.8M33.8M21.9M12.9M13.5M
Selling, general and administrative26.9M23.9M20.3M14.0M7.93M10.8M
Operating income-51.8M-64.3M-51.5M-32.7M-394.8K-18.8M
Depreciation and amortization327.0K308.0K287.0K222.0K181.0K137.0K
EBITDA-51.5M-64.0M-51.2M-32.4M-213.8K-18.6M
Interest expense1.15M297.0K1.40M1.30M927.0K
Income before tax-52.7M-61.0M-49.1M-33.6M-23.0M-21.4M
Income tax0119.1K-222.0K927.0K2.60M
Net income-52.7M-61.0M-49.1M-33.6M-378.8K-21.4M
Earnings per share, basic-1.11-1.66-1.48-2.24-0.02-1.04
Earnings per share, diluted-1.11-1.66-1.48-2.24-0.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents34.7M22.3M30.6M19.8M1.75M20.3M
Short-term investments71.8M44.6M57.0M63.9M958.0K15.4M
Receivables95.0K92.0K99.0K96.0K121.0K168.0K
Inventory310.0K173.0K146.0K276.0K68.0K69.0K
Current assets107.9M69.2M89.1M84.7M1.80M36.3M
Property, plant and equipment1.72M1.38M1.28M1.49M1.12M1.03M
Total assets114.9M76.2M95.2M95.6M161.8M38.1M
Accounts payable6.09M5.13M2.90M3.97M1.39K1.77M
Current liabilities16.7M16.2M11.2M18.6M165.5K14.4M
Long-term debt14.3M14.3M9.49M3.67M5.46M
Total debt15.0M15.0M1.69M11.9M5.67M9.46M
Total liabilities51.5M43.2M27.2M43.0M5.77M86.6M
Shareholders' equity53.6M33.0M68.0M52.5M-19.8M-48.5M
Shares outstanding57.0M38.2M35.8M20.2M4.45M20.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-49.0M-50.6M-46.1M-29.3M-272.4K-26.2M
Capital spending-489.0K-289.0K-78.0K-591.0K-274.0K-539.0K
Free cash flow-49.5M-50.8M-46.2M-29.9M-19.7M-26.7M
Cash from investing-26.9M13.1M10.7M-64.1M13.0M27.0M
Cash from financing88.3M29.2M46.2M103.3M-3.99M10.0M
Share buybacks-92.6M
Change in cash12.4M-8.30M10.8M9.85M-272.4K10.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
8-K · Current reportNov 9, 2026Material contractSEC
Show 200 filings
FilingDateTypeFiled with
424B5 · ProspectusNov 6, 2026Offer documentSEC
424B5 · ProspectusNov 5, 2026Offer documentSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
8-K · Current reportOct 1, 2026Current reportSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Meeting outcomeSEC
S-8 · Registration statement for employee plansJun 23, 2026Offer documentSEC
DEFA14A · Additional proxy materialJun 15, 2026Meeting noticeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 29, 2026Big-stake noticeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 27, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 25, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
8-K · Current reportFeb 13, 2026Management or board changeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 6, 2026Offer documentSEC
S-8 · Registration statement for employee plansFeb 6, 2026Offer documentSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
424B3 · ProspectusNov 21, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeNov 19, 2025Big-stake noticeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025Current reportSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
S-3 · Registration statementOct 31, 2025Offer documentSEC
8-K · Current reportOct 30, 2025Current reportSEC
8-K · Current reportOct 28, 2025Material contractSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipAug 6, 2025Insider tradeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
8-K · Current reportAug 4, 2025Material contractSEC
424B5 · ProspectusAug 1, 2025Offer documentSEC
424B5 · ProspectusJul 31, 2025Offer documentSEC
8-K · Current reportJul 31, 2025Material contractSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
144 · Notice of proposed saleJun 26, 2025Other filingsSEC
8-K · Current reportJun 24, 2025Meeting outcomeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 1, 2025Big-stake noticeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
8-K · Current reportApr 29, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 29, 2025Big-stake noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
8-K · Current reportMar 3, 2025Current reportSEC
8-K · Current reportFeb 25, 2025Management or board changeSEC
S-8 · Registration statement for employee plansFeb 19, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2025Insider tradeSEC
8-K · Current reportFeb 5, 2025Management or board changeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 23, 2024Big-stake noticeSEC
4 · Change in ownershipSep 26, 2024Insider tradeSEC
4 · Change in ownershipSep 10, 2024Insider tradeSEC
4 · Change in ownershipSep 10, 2024Insider tradeSEC
144 · Notice of proposed saleSep 10, 2024Other filingsSEC
144 · Notice of proposed saleSep 10, 2024Other filingsSEC
144 · Notice of proposed saleSep 9, 2024Other filingsSEC
144 · Notice of proposed saleSep 9, 2024Other filingsSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
144 · Notice of proposed saleSep 6, 2024Other filingsSEC
144 · Notice of proposed saleSep 6, 2024Other filingsSEC
144 · Notice of proposed saleSep 5, 2024Other filingsSEC
144 · Notice of proposed saleSep 4, 2024Other filingsSEC
4 · Change in ownershipAug 15, 2024Insider tradeSEC
8-K · Current reportAug 12, 2024Current reportSEC
424B5 · ProspectusAug 12, 2024Offer documentSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 7, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedAug 7, 2024Big-stake noticeSEC
4 · Change in ownershipAug 7, 2024Insider tradeSEC
8-K · Current reportJul 30, 2024Management or board changeSEC
3 · Initial statement of ownershipJul 30, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 17, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 17, 2024Big-stake noticeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 20, 2024Meeting outcomeSEC
8-K · Current reportJun 11, 2024Current reportSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC

This page holds 200 of 423 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Orchestra BioMed Holdings, Inc.’s releases · as of Nov 10, 2026

Common shares
78,704,957
Fully diluted
78,704,957

Fully diluted

LineSharesAs of
Common shares78,704,957Nov 9, 2026

Share count over time

CountShares
Nov 22, 202678,704,957
Nov 9, 202695,954,957
Nov 9, 202678,704,957

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Rtw Investments, LP9.56M12.1%US$59.4MSep 30, 2026
Perceptive Advisors LLC5.04M6.4%US$31.3MSep 30, 2026
UBS3.29M4.2%US$20.5MSep 30, 2026
BlackRock2.72M3.4%US$16.9MSep 30, 2026
Vanguard2.6M3.3%US$16.2MSep 30, 2026
Geode Capital1M1.3%US$6.25MSep 30, 2026
Masters Capital Management LLC1M1.3%US$6.22MSep 30, 2026
Propel Bio Management, LLC897K1.1%US$5.58MSep 30, 2026
Rice Hall James & Associates, LLC838K1.1%US$5.21MSep 30, 2026
State Street606K0.77%US$3.77MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Schwab413K0.52%US$2.57MSep 30, 2026
Alyeska Investment Group, L.P.400K0.51%US$2.49MSep 30, 2026
Goldman Sachs382K0.49%US$2.38MSep 30, 2026
Northern Trust343K0.44%US$2.14MSep 30, 2026
Knott David M Jr254K0.32%US$1.58MSep 30, 2026
Simplify Asset Management Inc.219K0.28%US$1.36MSep 30, 2026
Informed Momentum Co LLC128K0.16%US$799KSep 30, 2026
Daytona Street Capital LLC123K0.16%US$744KSep 30, 2026
BNY91,6730.12%US$570KSep 30, 2026
IFP Advisors, Inc90,5280.12%US$563KSep 30, 2026
Bridgeway Capital Management, LLC79,3700.10%US$494KSep 30, 2026
Sei Investments Co77,5990.10%US$483KSep 30, 2026
Two Sigma74,5630.09%US$464KSep 30, 2026
Empowered Funds, LLC72,2700.09%US$450KSep 30, 2026
Nuveen63,9580.08%US$398KSep 30, 2026
Susquehanna52,8230.07%US$329KSep 30, 2026
Holos Integrated Wealth LLC51,5950.07%US$292KSep 30, 2026
NewEdge Advisors, LLC44,1060.06%US$274KSep 30, 2026
Morgan Stanley42,1330.05%US$262KSep 30, 2026
Bank of America41,4150.05%US$258KSep 30, 2026
HighTower Advisors, LLC38,4620.05%US$239KSep 30, 2026
DWS34,7690.04%US$216KSep 30, 2026
T. Rowe Price32,6890.04%US$204KSep 30, 2026
XTX Topco Ltd31,2820.04%US$195KSep 30, 2026
Rhumbline Advisers30,7050.04%US$191KSep 30, 2026
Meramec Financial Planners, LLC30,0000.04%US$170KSep 30, 2026
Invesco26,2740.03%US$163KSep 30, 2026
Barclays25,0290.03%US$156KSep 30, 2026
MetLife Investment Management, LLC24,6870.03%US$154KSep 30, 2026
Citadel24,1520.03%US$150KSep 30, 2026
JPMorgan23,9650.03%US$146KSep 30, 2026
Jump Financial, LLC21,9000.03%US$136KSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.19,0510.02%US$118KSep 30, 2026
LPL Financial LLC17,4740.02%US$109KSep 30, 2026
Sargent Investment Group, LLC16,2500.02%US$101KSep 30, 2026
Engineers Gate Manager LP13,5350.02%US$84,188Sep 30, 2026
Creative Planning13,4650.02%US$83,752Sep 30, 2026
ABLE Financial Group, LLC13,4020.02%US$83,360Sep 30, 2026
Frec Markets, Inc.13,0480.02%US$81,159Sep 30, 2026
Wells Fargo12,1120.02%US$75,337Sep 30, 2026

This page holds 50 of 89 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.47M1.9%US$6.34MJun 30, 2026
iShares Russell 2000 ETF831K1.1%US$3.58MJun 30, 2026
Vanguard Extended Market Index Fund499K0.63%US$2.15MJun 30, 2026
Fidelity Small Cap Index Fund429K0.54%US$1.71MJul 31, 2026
iShares Russell 2000 Growth ETF374K0.48%US$1.62MJun 30, 2026
Simplify Propel Opportunities ETF219K0.28%US$947KJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio206K0.26%US$806KMay 29, 2026
Fidelity Extended Market Index Fund206K0.26%US$804KMay 31, 2026
Schwab U.S. Small-Cap ETF178K0.23%US$697KMay 31, 2026
iShares Micro-Cap ETF134K0.17%US$577KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Schwab Small-Cap Index Fund97,2540.12%US$387KJul 31, 2026
Clearwater Select Equity Fund86,4240.11%US$373KJun 30, 2026
Master Small Cap Index Series74,5010.09%US$321KJun 30, 2026
Ultra-Small Company Market Fund73,5000.09%US$317KJun 30, 2026
Fidelity Total Market Index Fund72,8380.09%US$285KMay 31, 2026
Fidelity Series Total Market Index Fund59,0220.07%US$231KMay 31, 2026
Nuveen Small Cap Blend Index Fund52,1180.07%US$207KJul 31, 2026
Fidelity Nasdaq Composite Index Fund45,4560.06%US$178KMay 31, 2026
Schwab U.S. Broad Market ETF43,6360.06%US$171KMay 31, 2026
EQ/2000 Managed Volatility Portfolio41,4250.05%US$179KJun 30, 2026
Schwab Total Stock Market Index Fund40,4960.05%US$161KJul 31, 2026
Fidelity Small Cap Growth Index Fund37,2260.05%US$161KJun 30, 2026
LVIP State Street Small-Cap Index Fund30,3000.04%US$131KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund27,3150.03%US$118KJun 30, 2026
Vanguard Balanced Index Fund26,9060.03%US$116KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund20,2070.03%US$87,193Jun 30, 2026
Global X Russell 2000 ETF19,0570.02%US$75,847Jul 31, 2026
Small Cap Index Fund18,4420.02%US$79,577Jun 30, 2026
MetLife Russell 2000 Index Portfolio14,6480.02%US$63,206Jun 30, 2026
Health Sciences Portfolio12,5120.02%US$53,989Jun 30, 2026
Small-Cap Index Portfolio10,9630.01%US$47,305Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund9,9140.01%US$39,458Jul 31, 2026
Small Cap Core Fund9,6200.01%US$41,510Jun 30, 2026
1290 VT Micro Cap Portfolio9,0280.01%US$38,956Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio8,7100.01%US$37,584Jun 30, 2026
NVIT Small Cap Index Fund8,5050.01%US$36,699Jun 30, 2026
DWS Small Cap Index VIP6,295<0.01%US$27,163Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio6,056<0.01%US$26,132Jun 30, 2026
T. Rowe Price Small-Cap Index Fund6,009<0.01%US$25,929Jun 30, 2026
BlackRock Small Cap Index V.I. Fund5,157<0.01%US$22,252Jun 30, 2026
GuideMark Small/Mid Cap Core Fund4,956<0.01%US$21,385Jun 30, 2026
SA Small Cap Index Portfolio4,667<0.01%US$18,575Jul 31, 2026
PD Small-Cap Growth Index Portfolio3,693<0.01%US$15,935Jun 30, 2026
CVT Russell 2000 Small Cap Index Portfolio3,617<0.01%US$15,607Jun 30, 2026
Nationwide Small Cap Index Fund3,455<0.01%US$13,751Jul 31, 2026
Venerable Small Cap Index Fund3,187<0.01%US$13,752Jun 30, 2026
Avantis U.S. Small Cap Equity ETF3,182<0.01%US$12,442May 31, 2026
SmallCap Growth Fund I3,048<0.01%US$12,131Jul 31, 2026
Invesco Nasdaq Biotechnology ETF2,983<0.01%US$11,664May 31, 2026
EQ/AB Small Cap Growth Portfolio2,300<0.01%US$9,925Jun 30, 2026

This page holds 50 of 64 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Rtw Investments, LP
10% owner
Buy1,200,000USD 5.00US$6MNov 9, 2026
Taylor Andrew Lawrence
Officer: Chief Financial Officer
Buy1,000USD 5.00US$5,000Nov 9, 2026
Hochman David P
Director, Officer: See Remarks
Buy5,000USD 5.00US$25,000Nov 9, 2026
Pacitti David
Director
Buy20,000USD 5.00US$100KNov 9, 2026
Fain Eric S
Director
Buy20,000USD 5.00US$100KNov 9, 2026
Sherman Darren
Director, Officer: See Remarks
Sale15,000USD 5.74US$86,100Nov 2, 2026
Sherman Darren
Director, Officer: See Remarks
Sale15,000USD 6.36US$95,400Oct 1, 2026
Hochman David P
Director, Officer: See Remarks
Buy10,000USD 4.79US$47,900Sep 3, 2026
Sherman Darren
Director, Officer: See Remarks
Sale15,000USD 4.94US$74,100Sep 1, 2026
Sherman Darren
Director, Officer: See Remarks
Buy2,000USD 5.33US$10,660Aug 26, 2026
All 19 trades
TradeTradeSharesPriceValueDate
Sherman Darren
Director, Officer: See Remarks
Sale15,000USD 4.09US$61,350Aug 3, 2026
Sherman Darren
Director, Officer: See Remarks
Sale15,000USD 4.27US$64,050Jul 1, 2026
Sherman Darren
Director, Officer: See Remarks
Sale15,000USD 3.87US$58,050Jun 1, 2026
Hochman David P
Director, Officer: See Remarks
Buy5,000USD 3.83US$19,150Jun 1, 2026
Aryeh Jason
Director
Buy665USD 3.75US$2,494May 18, 2026
Hochman David P
Director, Officer: See Remarks
Buy5,000USD 3.77US$18,850May 15, 2026
Aryeh Jason
Director
Buy8,971USD 3.90US$34,987May 15, 2026
Fain Eric S
Director
Buy20,000USD 4.13US$82,600May 14, 2026
Rtw Investments, LP
10% owner
Sale32USD 4.13US$132Apr 27, 2026

Big stakes

StakeStakeSharesDateFiling
Medtronic plc17.80%10.1MDec 31, 2025Schedule 13G
Rtw Investments, LP16.20%13.1MNov 9, 2026Schedule 13D
Perceptive Advisors LLC8.15%6.54MSep 30, 2026Schedule 13G
Dana Lorenzo5.50%3.1MNov 15, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jason M. Aryeh
Other companies: Lifecore Biomedical, Inc. (Director · Since at least Aug 15, 2024); Anebulo Pharmaceuticals, Inc. (Board Member · Since at least May 6, 2021); Ligand Pharmaceuticals Incorporated (Director · Since at least May 30, 2007); Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 19, 2017 · Past); Novelion Therapeutics Inc (Director · Jun 4, 2012 – May 15, 2017 · Past); Myrexis Inc (Director · Oct 19, 2011 – Jun 18, 2012 · Past); Vaxart, Inc. (Director · May 18, 2007 – May 25, 2011 · Past)
Director · Since at least Jan 26, 2023
Pedro P Granadillo
Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2018); Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past); NPS Pharmaceuticals Inc (Director · Nov 17, 2010 – Feb 21, 2015 · Past); Dendreon Corp (Director · Oct 7, 2009 – Jan 3, 2014 · Past); Capricor Therapeutics, Inc. (Director · Oct 16, 2007 – May 10, 2011 · Past); Haemonetics Corporation (Director · May 5, 2006 – Nov 8, 2018 · Past); First Indiana Corp (Director · Jan 3, 2006 – Jan 2, 2008 · Past)
Director · Aug 3, 2020 – Aug 3, 2020 · Past
Carsten Boess
Other companies: Atrium Therapeutics, Inc. (Director · Since at least Nov 10, 2025); Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 11, 2016); Synageva BioPharma Corp (SVP, Chief Financial Officer · Nov 2, 2011 – Jun 22, 2015 · Past); Insulet Corporation (Vice President, International · May 14, 2007 – Apr 25, 2011 · Past)
Director · Aug 3, 2020 – Aug 3, 2020 · Past
Eric A Md Rose
Other companies: ABIOMED Inc (Director · May 30, 2007 – Aug 10, 2022 · Past); SIGA Technologies Inc. (Director · Dec 19, 2006 – Jun 15, 2021 · Past); Keryx Biopharmaceuticals Inc (Director · Mar 14, 2006 – Nov 14, 2008 · Past); Nephros, Inc. (Director · Feb 2, 2006 – Jun 10, 2009 · Past)
Director · Jan 26, 2023 – Jun 20, 2024 · Past
David Pacitti
Other companies: Avanos Medical, Inc. (Chief Executive Officer · Since at least Mar 17, 2025); Apollo Endosurgery Inc (Director · Nov 13, 2017 – Apr 4, 2023 · Past)
Board Member · Since at least Mar 26, 2024
David P. Hochman
Other companies: Motus GI Holdings, Inc. (Director · Feb 13, 2018 – Feb 13, 2019 · Past); Corbus Pharmaceuticals Holdings, Inc. (Director · Nov 10, 2017 – May 20, 2020 · Past)
See Remarks, Director · Since at least Jan 26, 2023
Naveen Yalamanchi
Other companies: Immunovant, Inc. (Vice President and CFO, Director · May 9, 2019 – May 9, 2019 · Past); Rocket Pharmaceuticals, Inc. (Director · Jan 4, 2018 – Jun 13, 2024 · Past)
Chief Financial Officer, Director · Aug 3, 2020 – Aug 3, 2020 · Past
Pamela Connealy
Other companies: Pyxis Oncology, Inc. (CFO & COO · Oct 7, 2021 – Mar 31, 2025 · Past); Immunovant, Inc. (Chief Financial Officer · Dec 18, 2019 – Mar 19, 2021 · Past)
Board Member, Audit Committee Chair · Since at least Jan 26, 2023
Alice Lee
Other companies: Immunovant, Inc. (VPO, Secretary and Treasurer · May 9, 2019 – May 9, 2019 · Past)
VP Operations, Sec & Treasurer · Aug 3, 2020 – Aug 4, 2020 · Past
Andrew Taylor
Other companies: Motus GI Holdings, Inc. (Chief Financial Officer · Feb 13, 2018 – Feb 10, 2022 · Past)
Chief Financial Officer · Since at least Jun 6, 2023
All 37 people
PersonSeat
Darren R. Sherman
Other companies: Motus GI Holdings, Inc. (Director · Oct 12, 2020 – Feb 10, 2022 · Past)
See Remarks, Director · Since at least Jan 26, 2023
Mark Pomeranz
Other companies: Motus GI Holdings, Inc. (President and COO, Director · Feb 13, 2018 – Feb 10, 2022 · Past)
Executive Vice President and General Manager, Interventional Therapies · Since at least Nov 4, 2026
Michael Burkes Brophy
Other companies: Natera, Inc. (CHIEF FINANCIAL OFFICER · Since at least Feb 1, 2017)
Director · Aug 3, 2020 – Aug 3, 2020 · Past
Stephanie A Sirota
Other companies: Immunovant, Inc. (VP of CSC · May 9, 2019 – May 9, 2019 · Past)
VP of Corp Stratege and Comm · Aug 3, 2020 – Aug 4, 2020 · Past
Stuart Walter Peltz
Other companies: PTC Therapeutics, Inc. (CHIEF EXECUTIVE OFFICER, Director · Jun 19, 2013 – Jan 31, 2023 · Past)
Director · Aug 3, 2020 – Aug 3, 2020 · Past
Amy BermanVice President, Clinical Operations · Since at least Nov 4, 2026
Avi FischerSenior Vice President, Medical Affairs and Innovation · Since at least Oct 22, 2026
Bill LittleExecutive Vice President, Corporate Development and Strategy · Since at least Nov 4, 2026
Bob LaughnerSenior Vice President of Regulatory and Quality · Since at least Nov 4, 2026
Chris ClearyDirector · Since at least Jan 30, 2025
Chris ClearyBoard Member · Since at least Aug 14, 2026
Eric FainDirector · Since at least Jan 26, 2023
Geoffrey Wade SmithDirector · Jan 26, 2023 – Jul 20, 2023 · Past
George PapandreouSee Remarks · Sep 19, 2023 – May 8, 2024 · Past
Hans-Peter StollSenior Vice President, Medical Director · Since at least Nov 4, 2026
Heather BuckleyVice President, Marketing · Since at least Nov 4, 2026
John MackDirector · Since at least Jul 29, 2024
John SieckhausVice President, Global Field Clinical Engineering · Since at least Nov 4, 2026
Joshua AielloPrincipal Accounting Officer · Since at least Jan 26, 2023
Juan LorenzoSenior Vice President of Product Development · Since at least Nov 4, 2026
Kunal FalduVice President, Pharmaceutical Development, Focal Therapies · Since at least Nov 4, 2026
Lisa DanielsVice President, Human Resources · Since at least Nov 4, 2026
Michael KaswanChief Financial Officer · Jan 26, 2023 – Apr 12, 2023 · Past
William BaumbachVice President, Scientific Affairs, Focal Therapies · Since at least Nov 4, 2026
William Reed LittleSee Remarks · Jun 1, 2023 – May 30, 2024 · Past
Yuval MikaGeneral Manager and Chief Technology Officer, Bioelectronic Therapies · Since at least Aug 26, 2025
Ziv BelskyVice President, Research & Development, Bioelectronic Therapies · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Orchestra BioMed Holdings, Inc.